Metformin is Protective Against the Development of Mood Disorders
Pharmacopsychiatry · 01.01.2023 · 56 (01) · 25-31
DOI: 10.1055/a-1936-3580 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmacopsychiatry, erschienen am 01.01.2023. Verfasst von Jacqueline Lake und 15 weiteren Autor:innen. Beteiligte Einrichtung: Deakin University, IMPACT, The Institute for Mental and Physical Health and Clinical Translation, School of Medicine, Geelong, VIC, Australia. Hauptthemen laut MEDLINE: Metformin, Diabetes Mellitus, Type 2. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 46 Literaturangaben.
Abstract (Originalsprache)
Introduction
Mood disorders are a major cause of disability, and current treatment options are inadequate for reducing the burden on a global scale. The aim of this project was to identify drugs suitable for repurposing to treat mood disorders.
Methods
This mixed-method study utilized gene expression signature technology and pharmacoepidemiology to investigate drugs that may be suitable for repurposing to treat mood disorders.
Results
The transcriptional effects of a combination of drugs commonly used to treat mood disorders included regulation of the steroid and terpenoid backbone biosynthesis pathways, suggesting a mechanism involving cholesterol biosynthesis, and effects on the thyroid hormone signaling pathway. Connectivity Map analysis highlighted metformin, an FDA-approved treatment for type 2 diabetes, as a drug having global transcriptional effects similar to the mood disorder drug combination investigated. In a retrospective cohort study, we found evidence that metformin is protective against the onset of mood disorders.
Discussion
These results provide proof-of-principle of combining gene expression signature technology with pharmacoepidemiology to identify potential novel drugs for treating mood disorders. Importantly, metformin may have utility in the treatment of mood disorders, warranting future randomized controlled trials to test its efficacy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Deakin University, IMPACT, The Institute for Mental and Physical Health and Clinical Translation, School of Medicine, Geelong, VIC, Australia.
- Department of Medicine-Western Health, University of Melbourne, St Albans, Australia.
- Department of Epidemiology and Preventive Medicine, Monash University, Prahran, Australia.
- Barwon Health, Geelong, Australia.
- The Florey Institute of Neuroscience and Mental Health, Parkville, Australia.
- Bioinformatics Core Research Facility (BCRF), Deakin University, Geelong, Australia.
Zitieren
APA
Lake, J., Bortolasci, C. C., Stuart, A. L., Pasco, J. A., Kidnapillai, S., Spolding, B., Truong, T. T. T., Panizzutti, B., Liu, Z. S. J., Dean, O. M., Crowley, T., Richardson, M., Kim, J. H., Berk, M., Williams, L. J., & Walder, K. (2023). Metformin is Protective Against the Development of Mood Disorders. Pharmacopsychiatry, 56(01), 25-31. https://doi.org/10.1055/a-1936-3580
Vancouver
Lake J, Bortolasci CC, Stuart AL, Pasco JA, Kidnapillai S, Spolding B, et al. Metformin is Protective Against the Development of Mood Disorders. Pharmacopsychiatry. 2023;56(01):25-31. doi:10.1055/a-1936-3580
BibTeX
@article{Lake2023,
author = {Lake, Jacqueline and Bortolasci, Chiara C and Stuart, Amanda L and Pasco, Julie A and Kidnapillai, Srisaiyini and Spolding, Briana and Truong, Trang T T and Panizzutti, Bruna and Liu, Zoe S J and Dean, Olivia M and Crowley, Tamsyn and Richardson, Mark and Kim, Jee Hyun and Berk, Michael and Williams, Lana J and Walder, Ken},
title = {Metformin is Protective Against the Development of Mood Disorders},
journal = {Pharmacopsychiatry},
year = {2023},
volume = {56},
number = {01},
pages = {25--31},
doi = {10.1055/a-1936-3580}
}
EUVIMED